Abstract
Abstract
Background:
Medical practitioners face the challenge of noncompliance with prescriptions, particularly in chronic, asymptomatic, diseases such as osteoporosis.
Objective:
The aim of this study was to assess the raloxifene compliance and continuance rates and adverse effects over 24 months in clinical practice.
Methods:
Using a retrospective study of clinical histories obtained from a database at the Metabolic Research Institute, University of El Salvador School of Medicine, Buenos Aires, Argentina, as well as telephone interviews, we assessed compliance and continuance with raloxifene therapy in post-menopausal patients who had received prescriptions for raloxifene to prevent or treat osteoporosis. Patients were contacted by telephone 24 months after they had received a prescription for raloxifene. Compliance and continuance rates were calculated based on the data provided by the patients.
Results:
Data from 419 patients (mean [SD] age, 61.4 [7.4] years [range, 42–90 years]) were included in the study. At the time of the telephone interview, 225 (53.7%) were still receiving raloxifene, 105 (25.1%) had stopped treatment at their own discretion, 59 (14.1%) had not started treatment, and 30 (7.2%) had discontinued treatment as a result of advice from a physician. The reasons for not starting treatment were fear of thrombolytic events (21 patients [35.6%]); lack of interest in starting treatment (12 [20.3%]); other physician's advice (11 [18.6%]); family problems (3 [5.1%]); dissatisfaction with the prescribing physician, treatment cost, health problems unrelated to osteoporosis, and mistrust in the prescription (each, 2 [3.4%]); and advice from family/friends, fear of breast cancer, belief that raloxifene is hormonal, and that the patient was already polymedicated (each, 1 [1.7%]). Eleven of the 59 patients (18.6%) who had not started therapy were advised by a physician other than the prescribing physician not to start treatment and were excluded from the compliance analysis. Thus, the compliance analysis included 408 patients. The 2 most common reasons for discontinuing treatment at the patient's own discretion were health problems unrelated to osteoporosis (25 [23.8%]) and digestive problems not considered treatment related (16 [15.2%]). The compliance rates were 75.0%, 71.1%, 65.0%, 57.1%, and 52.0% at 3, 6, 12, 18, and 24 months, respectively. In patients who started raloxifene treatment, the continuance rates were 85.0%, 80.6%, 73.6%, 64.7%, and 58.9% at 3, 6, 12, 18, and 24 months, respectively. Sixty-two of the 135 patients who discontinued treatment did so within 3 months of receiving the prescription, accounting for 45.9% of all discontinuations.
Conclusions:
In the present study of raloxifene compliance and continuance in clinical practice, the compliance rate appeared to be relatively high compared with those of hormone-replacement therapy (HRT) and other non-HRT treatments. Almost half of patients who discontinued treatment did so in the first 3 months.
Key words: compliance, adherence, raloxifene
Full Text
The Full Text of this article is available as a PDF (448.3 KB).
References
- 1.Eraker SA, Kirscht JP, Becker MH. Understanding and improving patient compliance. Ann Intern Med. 1984;100:258–268. doi: 10.7326/0003-4819-100-2-258. [DOI] [PubMed] [Google Scholar]
- 2.Haynes RB, Taylor DW, Sakert DL. The Johns Hopkins University Press; New York: 1979. Compliance in Health Care. [Google Scholar]
- 3.Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990;150:841–845. [PubMed] [Google Scholar]
- 4.Achieving long-term continuance of menopausal ERT/HRT: Consensus opinion of the North America Menopause Society. Menopause. 1998;5:69–76. [PubMed] [Google Scholar]
- 5.Ettinger B, Black DM, Mitlak BH, for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators Reduction of vertebral fracture risk in post-menopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA. 1999;282:637–645. doi: 10.1001/jama.282.7.637. [published correction appears in JAMA. 1999;282:2124] [DOI] [PubMed] [Google Scholar]
- 6.Delmas PD, Bjarnason NH, Mitlak BH. Effects of raloxifene on bone mineral density, serum cholesterol, concentration, and uterine endometrium in post-menopausal women. N Engl J Med. 1997;337:1641–1647. doi: 10.1056/NEJM199712043372301. [DOI] [PubMed] [Google Scholar]
- 7.Black DM, Cummings SR, Karpf DB, for the Fracture Intervention Trial Research Group Randomised trial of effect of alendronate on the risk of fracture in women with existing vertebral fracture. Lancet. 1996;348:1535–1541. doi: 10.1016/s0140-6736(96)07088-2. [DOI] [PubMed] [Google Scholar]
- 8.Jones MM, Francis RM, Nordin BE. Five year follow-up of oestrogen therapy in 94 women. Maturitas. 1982;4:123–130. doi: 10.1016/0378-5122(82)90038-x. [DOI] [PubMed] [Google Scholar]
- 9.Ravnikar VA. Compliance with hormone therapy. Am J Obstet Gynecol. 1987;156:1332–1334. doi: 10.1016/0002-9378(87)90173-6. [DOI] [PubMed] [Google Scholar]
- 10.Wallace WA, Price VH, Elliot CA. Hormone replacement therapy acceptability to Nottingham post-menopausal women with a risk factor for osteoporosis. J R Soc Med. 1990;83:699–701. doi: 10.1177/014107689008301109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med. 1975;293:1167–1170. doi: 10.1056/NEJM197512042932303. [DOI] [PubMed] [Google Scholar]
- 12.Ettinger B, Pressman A, Silver P. Effect of age on reasons for initiation and discontinuation of hormone replacement therapy. Menopause. 1999;6:282–289. doi: 10.1097/00042192-199906040-00003. [published correction appears in Menopause. 2000;7:135] [DOI] [PubMed] [Google Scholar]
- 13.Hammond CB. Women's concerns with hormone replacement therapy—compliance issues. Fertil Steril. 1994;62(Suppl 2):157S–160S. [PubMed] [Google Scholar]
- 14.Ettinger B, Pressman A, Schein J. Use of alendronate in 812 women: Prevalence of gastrointestinal disturbances, lack of instructions, compliance and discontinuation. J Manag Care Pharm. 1998:488–492. [Google Scholar]
- 15.Mersfelder T, Armitstead JA, Ivey MF. A medication use evaluation of alendronate: Compliance with administration guidelines. Pharm Pract Manag Q. 1999;18:50–58. [PubMed] [Google Scholar]
- 16.Kayser J, Ettinger B, Pressman A. Postmenopausal hormonal support: Discontinuation of raloxifene versus estrogen. Menopause. 2001;8:323–332. doi: 10.1097/00042192-200109000-00006. [DOI] [PubMed] [Google Scholar]
- 17.American Association of Retired Persons; Baltimore, Md: 1984. Survey by Applied Research Techniques Conducted for the American Association of Retired Persons. [Google Scholar]
- 18.Upjohn; Washington, DC: 1985. National Prescription Buyers survey. [Google Scholar]
- 19.Rudd P. Clinicians and patients with hypertension: Unsettled issues about compliance. Am Heart J. 1995;130:572–579. doi: 10.1016/0002-8703(95)90368-2. [DOI] [PubMed] [Google Scholar]
- 20.Rudd P, Ahmed S, Zachary V. Compliance with medication timing: Implications from a medication trial for drug development and clinical practice. J Clin Res Pharmacoepidemiol. 1992;6:15–27. [Google Scholar]
- 21.Kruse WH. Compliance with treatment of hyperlipoproteinemia in medical practice and clinical trials. In: Cramer JA, Spilker B, editors. Patients Compliance in Medical Practice and Clinical Trials. Raven Press; Kalamazoo, Mich: 1991. pp. 175–186. [Google Scholar]
- 22.Cramer JA, Mattson RH. Monitoring compliance with antiepileptic drug therapy. In: Cramer JA, Spilker B, editors. Patients Compliance in Medical Practice and Clinical Trials. Raven Press; New York, NY: 1991. pp. 123–137. [Google Scholar]
- 23.Salzman C. Medication compliance in the elderly. J Clin Psychiatry. 1995;56(Suppl 1):18–22. [PubMed] [Google Scholar]
- 24.Johnston M, Clarke A, Mundy K. Facilitating comprehension of discharge medication in elderly patients. Age Ageing. 1986;15:304–306. doi: 10.1093/ageing/15.5.304. [DOI] [PubMed] [Google Scholar]